Here are the DEF 14A proxy statements from GeneDx Holdings Corp. (WGS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow WGS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WGS filings page.
GeneDx Holdings Corp. is holding its 2026 virtual annual meeting on June 18, 2026 to elect one Class II director, ratify Ernst & Young LLP as auditor, and conduct advisory votes on executive compensation and its voting frequency. The Board supports electing CEO Katherine Stueland as Class II director, ratifying Ernst & Young, approving executive pay, and holding say‑on‑pay votes every year.
The proxy highlights 2025 performance, including revenue of $427.5 million, 41% year‑over‑year growth, exome and genome test revenue of $360.3 million, adjusted gross margin of 71%, and adjusted net income of $41.8 million. Executive pay is structured around base salary, annual cash incentives, and equity awards, with increased use of performance‑based RSUs and new stock ownership and clawback policies.